Rifaximin in the treatment of recurrent Clostridium difficile infection (Q46549136)

23 December 2017

title

Rifaximin in the treatment of recurrent Clostridium difficile infection (English)

1 reference

23 December 2017

main subject

Clostridium difficile

0 references

rifaximin

1 reference

ChEBI release 2020-05-28

E Mattila

1

1 reference

23 December 2017

P Arkkila

2

1 reference

23 December 2017

P S Mattila

3

1 reference

23 December 2017

E Tarkka

4

1 reference

23 December 2017

P Tissari

5

1 reference

23 December 2017

V-J Anttila

6

1 reference

23 December 2017

language of work or name

English

0 references

publication date

24 October 2012

1 reference

23 December 2017

Alimentary Pharmacology & Therapeutics

published in

1 reference

23 December 2017

volume

37

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

122-128

1 reference

23 December 2017

Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options

cites work

1 reference

Comparative effectiveness of Clostridium difficile treatments: a systematic review

21 January 2018

1 reference

Best strategies in recurrent or persistent Clostridium difficile infection

21 January 2018

1 reference

Review article: faecal transplantation therapy for gastrointestinal disease

21 January 2018

1 reference

Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection

21 January 2018

1 reference

Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease

21 January 2018

1 reference

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

Treatment with monoclonal antibodies against Clostridium difficile toxins

21 January 2018

1 reference

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

21 January 2018

1 reference

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

21 January 2018

1 reference

Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea

21 January 2018

1 reference

Rifaximin: new therapeutic indication and future directions

21 January 2018

1 reference

Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea

21 January 2018

1 reference

Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

21 January 2018

1 reference

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

21 January 2018

1 reference

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

Predictors of serious complications due to Clostridium difficile infection

21 January 2018

1 reference

Predictors of first recurrence of Clostridium difficile infection: implications for initial management

21 January 2018

1 reference

Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection

21 January 2018

1 reference

Outcomes in community-acquired Clostridium difficile infection

21 January 2018

1 reference

Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease

21 January 2018

1 reference

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile

21 January 2018

1 reference

Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance

21 January 2018

1 reference

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.

21 January 2018

1 reference

Multidrug resistance in European Clostridium difficile clinical isolates

21 January 2018

1 reference

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

21 January 2018

1 reference

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

21 January 2018

1 reference

Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains

21 January 2018

1 reference

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection

21 January 2018

1 reference

Clostridium difficile ribotype does not predict severe infection

21 January 2018

1 reference

In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy

21 January 2018

1 reference

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

21 January 2018

1 reference

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12111

1 reference

23 December 2017

PubMed ID

23095030

1 reference

23 December 2017